. "Appendix 16: Mycobacterium tuberculosis." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vaccines for the 21st Century: A Tool for Decisionmaking
Table A16–2 Disease Scenarios for TB Infection
No. of Cases
% of Cases
Committee HUI Values
Duration (years)
Total Deaths (from acute infection)
1,476
Total Cases (reported)
22,795
Asymptomatic—suspect
suspect cases (treatment begun)
68,385
300.00%
1.0000
0.2500 (3 months)
Asymptomatic—latent infection
preventive treatment for latent infection
113,975
500.00%
1.0000
0.5000 (6 months)
Pulmonary TB
inpatient
20,060
88.00%
0.8700
0.0548 (20 days)
Pulmonary TB
outpatient
19,057
83.60%
0.8900
0.7500 (9 months)
Extrapulmonary TB
inpatient
2,735
12.00%
0.7200
0.0548 (20 days)
Extrapulmonary TB
outpatient
2,462
10.80%
0.8600
0.7500 (9 months)
60% of the targeted population in multi-drug-resistant areas would receive the vaccine.
Vaccine Schedule, Efficacy, and Costs
For the purposes of the calculations in this report, it was estimated that this vaccine would cost $50 per dose and that administration costs would be $10 per dose. Default assumptions of a 3-dose series and 75% effectiveness were accepted. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.
RESULTS
If a vaccine program for TB were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be $4,000. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 1,300.
